Skip to main content

Articles

Page 30 of 60

  1. Diabetes converts from a metabolic disorder into a predominantly vascular disease, once its duration extends over several years or/and when additional cardiovascular risk factors such as hypertension coexist. ...

    Authors: Dennis Kannenkeril, Agnes Bosch, Joanna Harazny, Marina Karg, Susanne Jung, Christian Ott and Roland E. Schmieder
    Citation: Cardiovascular Diabetology 2018 17:128
    Content type: Original investigation Published on:

  2. Type 2 diabetes mellitus (T2D), rapidly increasing to epidemic proportions, globally escalates cardiovascular disease risk. Although intensive interventions and comprehensive management of environmental risks ...

    Authors: Cheng Liu, Yanfang Li, Tianwang Guan, Yanxian Lai, Yan Shen, Abudurexiti Zeyaweiding, Haiyan Zhao, Fang Li and Tutiguli Maimaiti
    Citation: Cardiovascular Diabetology 2018 17:127
    Content type: Original investigation Published on:

  3. Ambiguity exists in relation to the role of physical activity (PA) for cardiovascular disease (CVD) risk reduction. We examined the interplay between PA dimensions and more conventional CVD risk factors to ass...

    Authors: Hanan Amadid, Nanna B. Johansen, Anne-Louise Bjerregaard, Søren Brage, Kristine Færch, Torsten Lauritzen, Daniel R. Witte, Annelli Sandbæk, Marit E. Jørgensen and Dorte Vistisen
    Citation: Cardiovascular Diabetology 2018 17:126
    Content type: Original investigation Published on:

  4. The study sought to assess the prognostic impact of type 2 diabetes in patients presenting with ventricular tachyarrhythmias on admission.

    Authors: Kathrin Weidner, Michael Behnes, Tobias Schupp, Jonas Rusnak, Linda Reiser, Armin Bollow, Gabriel Taton, Thomas Reichelt, Dominik Ellguth, Niko Engelke, Jorge Hoppner, Ibrahim El-Battrawy, Kambis Mashayekhi, Christel Weiß, Martin Borggrefe and Ibrahim Akin
    Citation: Cardiovascular Diabetology 2018 17:125
    Content type: Original investigation Published on:

  5. Women with history of hypertensive disorders of pregnancy (HDP) are at increased risk of early onset cardiovascular disease and type 2 diabetes (T2D). We aimed to investigate the extent to which HDP is also as...

    Authors: Simon Timpka, Amanda Markovitz, Tommy Schyman, Ingrid Mogren, Abigail Fraser, Paul W. Franks and Janet W. Rich-Edwards
    Citation: Cardiovascular Diabetology 2018 17:124
    Content type: Original investigation Published on:

  6. Diabetes is a leading cause of mortality and morbidity across the world. Over 50% of deaths among diabetic patients are caused by cardiovascular diseases. Cardiac diastolic dysfunction is one of the key early ...

    Authors: Beibei Dai, Huaping Li, Jiahui Fan, Yanru Zhao, Zhongwei Yin, Xiang Nie, Dao Wen Wang and Chen Chen
    Citation: Cardiovascular Diabetology 2018 17:123
    Content type: Original investigation Published on:

  7. For many years, cardiovascular disease (CVD) has been the leading cause of death around the world. Often associated with CVD are comorbidities such as obesity, abnormal lipid profiles and insulin resistance. I...

    Authors: Valeska Ormazabal, Soumyalekshmi Nair, Omar Elfeky, Claudio Aguayo, Carlos Salomon and Felipe A. Zuñiga
    Citation: Cardiovascular Diabetology 2018 17:122
    Content type: Review Published on:

  8. The incidence and prevalence of diabetes mellitus is rapidly increasing worldwide at an alarming rate. Type 2 diabetes mellitus (T2DM) is the most prevalent form of diabetes, accounting for approximately 90–95...

    Authors: Raminderjit Kaur, Manpreet Kaur and Jatinder Singh
    Citation: Cardiovascular Diabetology 2018 17:121
    Content type: Review Published on:

  9. The N-terminal prohormone of brain natriuretic peptide (NT-proBNP) is an important biomarker for the diagnosis of heart failure. Apart from this and only recently recognized, NT-proBNP levels associate with hi...

    Authors: Annette Masuch, Maik Pietzner, Martin Bahls, Kathrin Budde, Gabi Kastenmüller, Stephanie Zylla, Anna Artati, Jerzy Adamski, Henry Völzke, Marcus Dörr, Stephan B. Felix, Matthias Nauck and Nele Friedrich
    Citation: Cardiovascular Diabetology 2018 17:120
    Content type: Original investigation Published on:

  10. There is a vast disagreement in relation to the possible beneficial effects of omega-3 polyunsaturated fatty acids (omega-3 PUFA) supplementation in patients with diabetes and cardiovascular disease. The confl...

    Authors: Alexander Tenenbaum and Enrique Z. Fisman
    Citation: Cardiovascular Diabetology 2018 17:119
    Content type: Commentary Published on:

  11. There exist several predictive risk models for cardiovascular disease (CVD), including some developed specifically for patients with type 2 diabetes mellitus (T2DM). However, the models developed for a diabeti...

    Authors: James B. Young, Marjolaine Gauthier-Loiselle, Robert A. Bailey, Ameur M. Manceur, Patrick Lefebvre, Morris Greenberg, Marie-Hélène Lafeuille, Mei Sheng Duh, Brahim Bookhart and Carol H. Wysham
    Citation: Cardiovascular Diabetology 2018 17:118
    Content type: Original investigation Published on:

  13. Impaired glucose metabolism is an established risk factor for coronary artery disease. Previous studies revealed that glycemic variability (GV) is also important for glucose metabolism in patients with acute c...

    Authors: Hironori Takahashi, Noriaki Iwahashi, Jin Kirigaya, Shunsuke Kataoka, Yugo Minamimoto, Masaomi Gohbara, Takeru Abe, Kozo Okada, Yasushi Matsuzawa, Masaaki Konishi, Nobuhiko Maejima, Kiyoshi Hibi, Masami Kosuge, Toshiaki Ebina, Kouichi Tamura and Kazuo Kimura
    Citation: Cardiovascular Diabetology 2018 17:116
    Content type: Original investigation Published on:

  14. Unfortunately, after publication of this article [1], it was noticed that Table 1 contained errors introduced during the production process. In the WT + AT column, the FS value is 21 ± 7 and the Body Weight va...

    Authors: Maayan Waldman, Keren Cohen, Dor Yadin, Vadim Nudelman, Dan Gorfil, Michal Laniado-Schwartzman, Ran Kornwoski, Dan Aravot, Nader G. Abraham, Michael Arad and Edith Hochhauser
    Citation: Cardiovascular Diabetology 2018 17:115
    Content type: Correction Published on:

    The original article was published in Cardiovascular Diabetology 2018 17:111

  15. To improve outcomes in patients with diabetes mellitus (DM) undergoing percutaneous coronary intervention remain an unmet clinical need. The study aimed to evaluate the efficacy and safety of G2-DESs and BP-DE...

    Authors: Xiao-Fang Tang, Yuan-Liang Ma, Ying Song, Jing-Jing Xu, Yi Yao, Chen He, Huan-Huan Wang, Ping Jiang, Lin Jiang, Ru Liu, Zhan Gao, Xue-yan Zhao, Shu-Bin Qiao, Yue-Jin Yang, Run-Lin Gao, Bo Xu…
    Citation: Cardiovascular Diabetology 2018 17:114
    Content type: Original investigation Published on:

  16. Obesity is associated with type 2 diabetes mellitus, left ventricular diastolic dysfunction and heart failure but it is unclear to which extent it is related to left ventricular systolic dysfunction. The aim o...

    Authors: Peter Blomstrand, Peter Sjöblom, Mats Nilsson, Magnus Wijkman, Martin Engvall, Toste Länne, Fredrik H. Nyström, Carl Johan Östgren and Jan Engvall
    Citation: Cardiovascular Diabetology 2018 17:113
    Content type: Original investigation Published on:

  17. Although obesity-related type 2 diabetes mellitus (T2DM) and sarcopenia in the elderly have been increasing worldwide, the associations among visceral fat accumulation, skeletal muscle indices (mass, strength,...

    Authors: Jun Murai, Hitoshi Nishizawa, Akihito Otsuka, Shiro Fukuda, Yoshimitsu Tanaka, Hirofumi Nagao, Yasuna Sakai, Masahide Suzuki, Shinji Yokota, Hidetoshi Tada, Mayumi Doi, Yuya Fujishima, Shunbun Kita, Tohru Funahashi, Norikazu Maeda, Tadashi Nakamura…
    Citation: Cardiovascular Diabetology 2018 17:112
    Content type: Original investigation Published on:

  18. Metabolic disorders such as obesity, insulin resistance and type 2 diabetes mellitus (DM2) are all linked to diabetic cardiomyopathy that lead to heart failure. Cardiomyopathy is initially characterized by car...

    Authors: Maayan Waldman, Keren Cohen, Dor Yadin, Vadim Nudelman, Dan Gorfil, Michal Laniado-Schwartzman, Ran Kornwoski, Dan Aravot, Nader G. Abraham, Michael Arad and Edith Hochhauser
    Citation: Cardiovascular Diabetology 2018 17:111
    Content type: Original investigation Published on:

    The Correction to this article has been published in Cardiovascular Diabetology 2018 17:115

  19. Cardiovascular disease and kidney damage are tightly associated in people with type 2 diabetes. Experimental evidence supports a causal role for vasopressin (or antidiuretic hormone) in the development of diab...

    Authors: Gilberto Velho, Stéphanie Ragot, Ray El Boustany, Pierre-Jean Saulnier, Mathilde Fraty, Kamel Mohammedi, Frédéric Fumeron, Louis Potier, Michel Marre, Samy Hadjadj and Ronan Roussel
    Citation: Cardiovascular Diabetology 2018 17:110
    Content type: Original investigation Published on:

  21. Arterial stiffness is emerging as an independent risk factor for the development of chronic kidney disease. The sodium glucose co-transporter 2 (SGLT2) inhibitors, which lower serum glucose by inhibiting SGLT2...

    Authors: Annayya R. Aroor, Nitin A. Das, Andrea J. Carpenter, Javad Habibi, Guanghong Jia, Francisco I. Ramirez-Perez, Luis Martinez-Lemus, Camila M. Manrique-Acevedo, Melvin R. Hayden, Cornel Duta, Ravi Nistala, Eric Mayoux, Jaume Padilla, Bysani Chandrasekar and Vincent G. DeMarco
    Citation: Cardiovascular Diabetology 2018 17:108
    Content type: Original investigation Published on:

  22. The excess risks of mortality and cardiovascular morbidity among patients with type 2 diabetes mellitus (T2DM) is well known. In this nationwide study, we assessed risks of mortality and cardiovascular events ...

    Authors: Zoltán Kiss, György Rokszin, Zsolt Abonyi-Tóth, György Jermendy, Péter Kempler, Dániel Aradi and István Wittmann
    Citation: Cardiovascular Diabetology 2018 17:107
    Content type: Original investigation Published on:

  23. Sodium glucose co-transporter2 inhibitors reduce the incidence of cardiovascular events in patients with type 2 diabetes mellitus based on the results of recent cardiovascular outcome studies. Herein, we inves...

    Authors: Νarjes Nasiri-Ansari, Georgios K. Dimitriadis, Georgios Agrogiannis, Despoina Perrea, Ioannis D. Kostakis, Gregory Kaltsas, Athanasios G. Papavassiliou, Harpal S. Randeva and Eva Kassi
    Citation: Cardiovascular Diabetology 2018 17:106
    Content type: Original investigation Published on:

  24. Antioxidant enzymes play a fundamental role in counteracting oxidative stress induced by high glucose. Although mitochondrial superoxide dismutase (SOD2) is the principal defence against the toxicity of supero...

    Authors: Lucia La Sala, Simona Mrakic-Sposta, Stefano Micheloni, Francesco Prattichizzo and Antonio Ceriello
    Citation: Cardiovascular Diabetology 2018 17:105
    Content type: Original investigation Published on:

  25. Oxidative stress (OS) plays an important role in type 2 diabetes (T2D) pathogenesis and its complications. New therapies target natural antioxidants as an alternative and/or supplemental strategy to prevent an...

    Authors: Remmelt Van der Werf, Catherine Walter, William Bietiger, Elodie Seyfritz, Carole Mura, Claude Peronet, Julie Legrandois, Dalal Werner, Said Ennahar, Fabien Digel, Elisa Maillard-Pedracini, Michel Pinget, Nathalie Jeandidier, Eric Marchioni, Séverine Sigrist and Stéphanie Dal
    Citation: Cardiovascular Diabetology 2018 17:104
    Content type: Original investigation Published on:

  26. The cardiac hormones atrial (ANP) and B-type natriuretic peptides (BNP) moderate arterial blood pressure and improve energy metabolism as well as insulin sensitivity via their shared cGMP-producing guanylyl cy...

    Authors: Sabine Tauscher, Hitoshi Nakagawa, Katharina Völker, Franziska Werner, Lisa Krebes, Tamara Potapenko, Sören Doose, Andreas L. Birkenfeld, Hideo A. Baba and Michaela Kuhn
    Citation: Cardiovascular Diabetology 2018 17:103
    Content type: Original investigation Published on:

  27. Incretin-based therapies including dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon like peptide-1 (GLP-1) receptor agonists are novel medications for type 2 diabetes management. Several studies have fou...

    Authors: Ghadeer K. Dawwas, Steven M. Smith and Haesuk Park
    Citation: Cardiovascular Diabetology 2018 17:102
    Content type: Original investigation Published on:

  28. Hypertriglyceridemia, insulin resistance and hyperglycemia are risk factors for atherosclerosis in type 2 diabetes. Angiopoietin-like protein 8 (ANGPTL8) is a newly identified liver-derived hormone related to ...

    Authors: Tianpeng Zheng, Bo Ge, Hongbo Liu, Bo Chen, Linyuan Qin, Liuping Xiao and Jianfei Song
    Citation: Cardiovascular Diabetology 2018 17:84
    Content type: Original investigation Published on:

  29. Diabetes mellitus currently affects over 350 million patients worldwide and is associated with many deaths from cardiovascular complications. Sodium–glucose co-transporter 2 (SGLT-2) inhibitors are a novel cla...

    Authors: Charshawn Lahnwong, Siriporn C. Chattipakorn and Nipon Chattipakorn
    Citation: Cardiovascular Diabetology 2018 17:101
    Content type: Review Published on:

  30. The relationship between long-term glycemic variability (GV) represented by visit-to-visit HbA1c variability and baroreflex sensitivity (BRS) in type 2 diabetes mellitus (T2DM) has not been clarified by previo...

    Authors: Daisuke Matsutani, Masaya Sakamoto, Soichiro Minato, Yosuke Kayama, Norihiko Takeda, Ryuzo Horiuchi and Kazunori Utsunomiya
    Citation: Cardiovascular Diabetology 2018 17:100
    Content type: Original investigation Published on:

  31. Inhibiting both type 1 and 2 sodium–glucose linked cotransporter (SGLT1/2) offers the potential to not only increase glucosuria beyond that seen with selective SGLT2 inhibition alone but to reduce glucose abso...

    Authors: Kim A. Connelly, Yanling Zhang, Jean-François Desjardins, Kerri Thai and Richard E. Gilbert
    Citation: Cardiovascular Diabetology 2018 17:99
    Content type: Original investigation Published on:

  32. Randomized controlled trials (RCTs) suggest that supplementation with omega-3 polyunsaturated fatty acids (n-3PUFAs) may favourably modify cardiometabolic biomarkers in type 2 diabetes (T2DM). Previous meta-an...

    Authors: Lauren L. O’Mahoney, Jamie Matu, Oliver J. Price, Karen M. Birch, Ramzi A. Ajjan, Diane Farrar, Robyn Tapp, Daniel J. West, Kevin Deighton and Matthew D. Campbell
    Citation: Cardiovascular Diabetology 2018 17:98
    Content type: Review Published on:

  33. The aim of the present study was to examine the association of angiopoietin-like proteins-8 (ANGPTL8) rs2278426, cholesteryl ester-transfer protein (CETP) rs708272 and endothelial nitric oxide synthase (NOS3) rs1...

    Authors: Dalia El-Lebedy
    Citation: Cardiovascular Diabetology 2018 17:97
    Content type: Original investigation Published on:

  34. The prognostic impact of long-term glycemic variability on clinical outcomes in patients with heart failure (HF) and type 2 diabetes mellitus (T2DM) remains unclear. We determined and compared hemoglobin A1c (...

    Authors: Jun Gu, Jian-an Pan, Yu-qi Fan, Hui-li Zhang, Jun-feng Zhang and Chang-qian Wang
    Citation: Cardiovascular Diabetology 2018 17:96
    Content type: Original investigation Published on:

  35. As body fat composition and metabolism differ between men and women, we evaluated sex-related differences in the association among epicardial adipose tissue (EAT), secretome profile, and myocardial function of...

    Authors: Dong-Hyuk Cho, Hyung Joon Joo, Mi-Na Kim, Do-Sun Lim, Wan Joo Shim and Seong-Mi Park
    Citation: Cardiovascular Diabetology 2018 17:95
    Content type: Original investigation Published on:

  36. Patients with diabetes type 2 have an increased risk for cardiovascular disease and commonly use combination therapy consisting of the anti-diabetic drug metformin and a cholesterol-lowering statin. However, b...

    Authors: Mariël F. van Stee, Albert A. de Graaf and Albert K. Groen
    Citation: Cardiovascular Diabetology 2018 17:94
    Content type: Review Published on:

  37. Previous studies have documented that visceral adipose tissue is positively associated with the risk of diabetes. However, the association of subcutaneous adipose tissue with diabetes risk is still in dispute....

    Authors: Peizhu Chen, Xuhong Hou, Gang Hu, Li Wei, Lei Jiao, Hongmei Wang, Siyu Chen, Jingzhu Wu, Yuqian Bao and Weiping Jia
    Citation: Cardiovascular Diabetology 2018 17:93
    Content type: Original investigation Published on:

  38. Angiopoietin-like protein 8 (ANGPTL8), which is a novel hormone produced in liver and adipose tissue, is involved in regulating lipid metabolism. Patients with diabetes and coronary artery disease (CAD) have r...

    Authors: Xiaolu Jiao, Jiqiang He, Yunyun Yang, Song Yang, Juan Li and Yanwen Qin
    Citation: Cardiovascular Diabetology 2018 17:92
    Content type: Original investigation Published on:

  39. Recently, two large randomized controlled trials which only included patients with underlying cardiovascular disease (CVD) or patients at high risk for CVD showed that two sodium glucose co-transporter 2 inhib...

    Authors: Young-Gun Kim, Seung Jin Han, Dae Jung Kim, Kwan-Woo Lee and Hae Jin Kim
    Citation: Cardiovascular Diabetology 2018 17:91
    Content type: Original investigation Published on:

  40. Raised hemoglobinA1c (HbA1c) is an indicator of pre-diabetes, which is associated with increased risk of coronary artery disease. However, the detailed morphological characteristics of non-culprit plaques in a...

    Authors: Shaotao Zhang, Jiannan Dai, Haibo Jia, Sining Hu, Hongwei Du, Ning Li, Yongpeng Zou, Yanan Zou, Shenhong Jing, Yan Wang, Rong Sun and Bo Yu
    Citation: Cardiovascular Diabetology 2018 17:90
    Content type: Original investigation Published on:

  41. Calcium/calmodulin-dependent kinase II-delta (CaMKIIδ) activity is enhanced during hyperglycemia and has been shown to alter intracellular calcium handling in cardiomyocytes, ultimately leading to reduced card...

    Authors: Lorna J. Daniels, Rachel S. Wallace, Olivia M. Nicholson, Genevieve A. Wilson, Fiona J. McDonald, Peter P. Jones, J. Chris Baldi, Regis R. Lamberts and Jeffrey R. Erickson
    Citation: Cardiovascular Diabetology 2018 17:89
    Content type: Original investigation Published on:

  42. Local, abdominal fat depots may be related to alterations in cardiac function and morphology due to a metabolic linkage. Thus, we aimed to determine their association with subtle cardiac changes and the potent...

    Authors: Christopher L. Schlett, Roberto Lorbeer, Carolyn Arndt, Sigrid Auweter, Jürgen Machann, Holger Hetterich, Birgit Linkohr, Wolfgang Rathmann, Annette Peters and Fabian Bamberg
    Citation: Cardiovascular Diabetology 2018 17:88
    Content type: Original investigation Published on:

  43. Chronic low-grade inflammation and associated insulin resistance and metabolic abnormalities have been proposed as ‘common soil’ for diabetes mellitus (DM) and cardiovascular disease (CVD). This paper aimed to...

    Authors: Xue Bao, Yan Borné, Linda Johnson, Iram Faqir Muhammad, Margaretha Persson, Kaijun Niu and Gunnar Engström
    Citation: Cardiovascular Diabetology 2018 17:87
    Content type: Original investigation Published on:

  44. Recent studies reported that sodium glucose cotransporter 2 (SGLT2) inhibitors reduced the cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) compared to placebo in contras...

    Authors: Fumika Shigiyama, Naoki Kumashiro, Ayako Fuchigami and Takahisa Hirose
    Citation: Cardiovascular Diabetology 2018 17:86
    Content type: Study protocol Published on:

  45. Recent clinical trials investigating cardiovascular (CV) safety of newer antidiabetic agents have been rapidly and largely changing the landscape of diabetes care and providing highly important clinical inform...

    Authors: Atsushi Tanaka and Koichi Node
    Citation: Cardiovascular Diabetology 2018 17:85
    Content type: Commentary Published on:

  47. Advanced glycation end-products play a role in diabetic vascular complications. Their optical properties allow to estimate their accumulation in tissues by measuring the skin autofluorescence (SAF). We searche...

    Authors: C. Blanc-Bisson, F. L. Velayoudom-Cephise, A. Cougnard-Gregoire, C. Helmer, K. Rajaobelina, C. Delcourt, L. Alexandre, L. Blanco, K. Mohammedi, M. Monlun and V. Rigalleau
    Citation: Cardiovascular Diabetology 2018 17:82
    Content type: Original investigation Published on:

  48. Patients with type 2 diabetes (T2D) face a high amputation rate. We investigated the relationship between the level of amputation and the presence of micro or macro-vascular disease and related circulating bio...

    Authors: Fabrice Schneider, Pierre-Jean Saulnier, Elise Gand, Mathieu Desvergnes, Nicolas Lefort, Eric Thorin, Nathalie Thorin-Trescases, Kamel Mohammedi, Stéphanie Ragot, Jean-Baptiste Ricco and Samy Hadjadj
    Citation: Cardiovascular Diabetology 2018 17:81
    Content type: Original investigation Published on:

  49. Most studies linking long-term consequences of adolescent underweight and obesity are limited to men.

    Authors: Ariel Furer, Arnon Afek, Omri Orr, Liron Gershovitz, Moran Landau Rabbi, Estela Derazne, Orit Pinhas-Hamiel, Noam Fink, Adi Leiba, Amir Tirosh, Jeremy D. Kark and Gilad Twig
    Citation: Cardiovascular Diabetology 2018 17:80
    Content type: Original investigation Published on:

  50. Cardiovascular (CV) safety of one anti-diabetic medication over another remains partially delineated. We sought to assess the comparative effect on CV outcomes among novel anti-diabetic agents.

    Authors: Xiao-dong Zhuang, Xin He, Da-ya Yang, Yue Guo, Jian-gui He, Hai-peng Xiao and Xin-xue Liao
    Citation: Cardiovascular Diabetology 2018 17:79
    Content type: Review Published on:
journal logo

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Submit manuscript

Annual Journal Metrics

  • 2022 Citation Impact
    9.3 - 2-year Impact Factor
    9.6 - 5-year Impact Factor
    2.054 - SNIP (Source Normalized Impact per Paper)
    2.361 - SJR (SCImago Journal Rank)

    2023 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    56 days submission to accept (Median)

    2023 Usage 
    2,523,778 downloads
    3,115 Altmetric mentions 

Cardiovascular Diabetology

ISSN: 1475-2840